CN Patent

CN103304572A — 一类3-氰基喹啉类化合物及其药用组合物和应用

Assigned to Shanghai Pharmaceuticals Holding Co Ltd · Expires 2013-09-18 · 13y expired

What this patent protects

本发明涉及如式I所示的化合物或其药学上可接受的盐、溶剂化物、前体药物、立体异构体、互变异构体、多晶型物或代谢产物、其药物组合物和其药用用途。本发明所述的式I化合物或其药学上可接受的盐、溶剂化物、前体药物、立体异构体、互变异构体、多晶型物或代谢产物，及其药物组合物可作为蛋白激酶抑制剂使用，特别是用于治疗或预防肿瘤。

USPTO Abstract

本发明涉及如式I所示的化合物或其药学上可接受的盐、溶剂化物、前体药物、立体异构体、互变异构体、多晶型物或代谢产物、其药物组合物和其药用用途。本发明所述的式I化合物或其药学上可接受的盐、溶剂化物、前体药物、立体异构体、互变异构体、多晶型物或代谢产物，及其药物组合物可作为蛋白激酶抑制剂使用，特别是用于治疗或预防肿瘤。

Drugs covered by this patent

neratinib-maleate (NERATINIB MALEATE)

Patent Metadata

Patent number: CN103304572A
Jurisdiction: CN
Classification: —
Expires: 2013-09-18
Drug substance claim: No
Drug product claim: No
Assignee: Shanghai Pharmaceuticals Holding Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.